Vancouver, Canada (May 30th, 2023) – GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, announces record year-over-year quarterly sales growth for Q1 2023, as well as a record implementation time for getting its enterprise molecular lab and health system customers up-and-running in less than 30 days (elapsed).
The first quarter of 2023 represents significant growth for GenXys, reaching important milestones as it fosters new ties through licensing deals with molecular labs and health system companies across North America that are looking for cost-effective, reliable, and smart solutions. By implementing the GenXys software, companies are improving health outcomes by reducing the frequency and severity of adverse drug events, improve treatment effectiveness and adherence and save money through personalized prescribing with important pharmacogenetic (PGx) clinical results at the click of a button.
GenXys experienced high channel partner activity in addition to its best year-over-year quarter sales growth of 349% supported by significant net new license sales. With the continued success of GenXys’ software solutions and happy partners, 100% of installed enterprise customers have realized the value and transformative impact made by GenXys’ products and have chosen to renew their licenses. The company is also committed to remarkably efficient implementation timelines to get its software and the results into the hands of clinicians as quickly as possible. Recently for a New Jersey-based Health System customer, GenXys was able to get its award-winning precision prescribing software, with embedded PGx, up and running in their environment in less than 30 days.
“As North America’s category-defining clinical support tool for precision prescribing, we are proud of the number of patient datasets our software processes,” says Karl Pringle, CEO of GenXys. “Being a cloud-hosted and rules based algorithmic solution means all our customers are conforming to the latest clinical and pharmacogenetic guidelines set by CPIC, FDA, and other industry groups. Providing evidence-based prescribing support with real-time PGx inclusion is becoming a need-to-have, not a nice-to-have. This has been reinforced by recent advancements at every level of healthcare from policy to clinical trials, to reimbursement, and to clinical care and patient outcomes.”
Pharmacogenetic adoption is accelerating at pace in the delivery of healthcare and GenXys continues to be at the forefront of advocating for safer prescribing practices and reducing adverse drug reactions. GenXys actively supports PGx adoption across North America with a large US customer base, spanning nearly a quarter of all states. In certain US states, such as California, PGx-related legislation initiatives are in process and are paving the way for further acceleration of PGx use through mass reimbursement programs. California’s Assembly Bill 425 is showing Medi-Cal’s support for PGx coverage within its 12 million covered lives. It has recently received unanimous committee level agreement. GenXys is looking forward to continuing its mission for every prescription to be made better with its software supporting PGx initiatives and partnering with health systems, laboratories, and payers with similar missions of safer prescribing practices for all.
About GenXys Health Care Systems
GenXys, with a presence across North America, provides the world’s most comprehensive precision prescribing solutions with embedded pharmacogenetics to solve one of healthcare’s biggest challenges: inappropriate (“trial-and-error”) prescribing. GenXys’ clinical decision support software suite is in use by major insurance providers, health systems, pharmacies and their pharmacogenetic labs across North America. Ongoing global clinical studies are paving the way into geographical markets to enable GenXys to realize its vision of making every prescription better with its software to increase patient safety, improve population health, and reduce healthcare costs. genxys.com
Contact:
Media Relations and Interview Requests: media@genxys.com